Genflow Biosciences reported interim results from a randomized, blinded trial of its centenarian-derived SIRT6c gene therapy in 24 beagles over ten years old, with methylation age at Day 182 falling 1.08 years in the low-dose plasmid DNA group versus 0.07 years in controls. None of the between-group differences reached statistical significance, and frailty scores did not separate from control. Preliminary muscle histology showed preserved type II fibers and higher satellite-cell density, with the confirmatory methylation readout deferred to Day 320.
Key Points
- Methylation age fell 1.08 years in low-dose treated beagles
- Differences versus control were not statistically significant at Day 182
- Muscle histology showed preserved type II fibers, more satellite cells
Longevity Analysis
The central question is not whether an intervention moves an epigenetic clock but whether molecular, structural and functional measures agree — and here they only partially do, with histology ranking the AAV8 arm highest while the clock favored plasmid delivery. Late-life intervention targeting DNA repair and genomic maintenance remains one of the more plausible routes to preserving muscle tissue and regenerative capacity in aged mammals, but a single biomarker shifting in isolation is a signal to interpret, not a result to act on. The Day 320 confirmatory readout, and whether frailty and performance eventually track with the molecular data, will determine what this tells us about altering aging biology after it is already well advanced.
Original published by Longevity.Technology, by Eleanor Garth.